QIAGEN and Celera Establish Distribution Agreement for Respiratory Pathogen Panel
February 11 2010 - 6:00AM
Business Wire
QIAGEN N.V. (NASDAQ:QGEN; Frankfurt Prime Standard:QIA) and
Celera Corporation (NASDAQ:CRA) today announced an agreement under
which QIAGEN will distribute a Celera molecular multiplex assay.
The assay is the next generation version of QIAGEN’s ResPlex II
assay for detection of respiratory pathogens. Multiplex assays
allow testing for a multiple number of different pathogens in a
single run. Financial details were not disclosed.
Under the terms of the agreement, QIAGEN has the exclusive
worldwide rights to distribute this multiplex test kit, which will
be manufactured by Celera. The new ResPlex assay detects 19
different pathogens associated with respiratory infections and is
designed for use with LiquiChip (Luminex) 100 and 200 instrument
platforms.
“Celera’s significant experience in the development and
manufacturing of molecular diagnostic products is a very valuable
resource and this relationship can accelerate our effort to further
expand our molecular diagnostic solution portfolio,” said Peer
Schatz, CEO of QIAGEN. “We believe that this new product has the
potential to provide significant value for laboratories, healthcare
professionals and patients worldwide.”
“We are pleased to have entered into this agreement with QIAGEN
as we look toward the development and marketing of a molecular
diagnostic solution to address certain infectious respiratory
diseases and provide our customers with a product of the highest
quality,” said Kathy Ordoñez, CEO of Celera.
The new ResPlex kits will be available through QIAGEN’s existing
sales channels. The new test will be submitted for regulatory
approval in the United States and Europe.
About QIAGEN:
QIAGEN N.V., a Netherlands holding company, is the
leading global provider of sample and assay technologies.
Sample technologies are used to isolate and process DNA, RNA
and proteins from biological samples such as blood or
tissue. Assay technologies are used to make such isolated
bio-molecules visible. QIAGEN has developed and markets more than
500 sample and assay products as well as automated solutions for
such consumables. The company provides its products to
molecular diagnostics laboratories, academic researchers,
pharmaceutical and biotechnology companies, and applied
testing customers for purposes such as forensics, animal
or food testing and pharmaceutical process control. QIAGEN's
assay technologies include one of the broadest panels of molecular
diagnostic tests available worldwide. This panel includes the
digene HPV Test, which is regarded as a "gold standard" in testing
for high-risk types of human papillomavirus (HPV), the primary
cause of cervical cancer, as well as a broad suite of solutions for
infectious disease testing and companion diagnostics. QIAGEN
employs more than 3,500 people in over 30 locations worldwide.
Further information about QIAGEN can be found at
http://www.qiagen.com/.
QIAGEN SAFE HARBOR
STATEMENT
Statements contained in this release that are not historical
facts are forward-looking statements, including statements about
the new molecular multiplex assay and our products, markets and
strategy. Such statements are based on current expectations that
involve risks and uncertainties including, but not limited to,
those associated with: management of growth and international
operations (including currency fluctuations and logistics),
variability of our operating results, commercial development of our
markets (including applied testing, clinical and academic research,
proteomics, women’s health/HPV testing, molecular diagnostics,
personalized healthcare and companion diagnostics), our
relationships with customers, suppliers and strategic partners,
competition, changes in technology, fluctuations in demand,
regulatory requirements, identifying, developing and producing
integrated products differentiated from our competitors' products,
market acceptance of our products, and integration of acquired
technologies and businesses. For further information, refer to our
filings with the SEC, including our latest Form 20-F. Information
in this release is as of the date of the release, and we undertake
no duty to update this information unless required by law.
About Celera:
Celera is a healthcare business focusing on the integration of
genetic testing into routine clinical care through a combination of
products and services incorporating proprietary discoveries.
Berkeley HeartLab, a subsidiary of Celera, offers services to
predict cardiovascular disease risk and improve patient management.
Celera also commercializes a wide range of molecular diagnostic
products through Abbott and has licensed other relevant diagnostic
technologies developed to provide personalized disease management
in cancer. Information about Celera Corporation, including reports
and other information filed by the company with the Securities and
Exchange Commission, is available at http://www.celera.com.
Celera Forward-Looking Statements
Certain statements in this press release are forward-looking.
These may be identified by the use of forward-looking words or
phrases such as “believe,” “expect,” “will,” “should,”
“anticipate,” “may,” “could,” and “intend,” among others. These
forward-looking statements are based on Celera’s current
expectations. The Private Securities Litigation Reform Act of 1995
provides a "safe harbor" for such forward-looking statements. In
order to comply with the terms of the safe harbor, Celera notes
that a variety of factors could cause actual results and experience
to differ materially from the anticipated results or other
expectations expressed in such forward-looking statements. The
risks and uncertainties that may affect the operations,
performance, development, and results of our business include, but
are not limited to, the risks and uncertainties that: (1) the
agreement with QIAGEN may be terminated; (2) the risk that the
products contemplated by this agreement will not receive regulatory
approvals; and (3) the uncertainty that any products will be
accepted and adopted by the market, including the risk that these
products will not be competitive with tests offered by other
companies. The foregoing list sets forth some, but not all, of the
factors that could affect Celera's ability to achieve results
described in any forward-looking statements. For additional
information about the risks and uncertainties that Celera faces and
a discussion of its financial statements and footnotes, see
documents filed by Celera with the SEC, including its transition
report on Form 10-KT and all subsequent periodic reports. All
information in this press release is as of the date of the release,
and Celera does not undertake any duty to update this information,
including any forward-looking statements, unless required by
law.
Qiagen NV (TG:QIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Qiagen NV (TG:QIA)
Historical Stock Chart
From Jul 2023 to Jul 2024